The Positives
+ Revenue rose on the back of resilient patient load growth and increasing average patient bill sizes. Patient load grew 1.3% YoY to 116.2k patients, driven by both inpatient (+2.6% YoY) and outpatient (+1.1%YoY) growth from Mahkota (Mahkota Medical Centre, Melaka) and Regency (Regency Specialist Hospital, Johor). Average inpatient and outpatient bill size rose 4.9% and 5.3% YoY respectively. The continuous growth in patient load and larger bill sizes were due to the expansion of specialist offerings, further developments of HMI’s Centres of Excellence (COE), investments in specialised medical technology and recruitment of more specialists and sub-specialists. Increasingly complex and acute cases will contribute to revenue intensity. Meanwhile, local and foreign patient load mix remained unchanged YoY at 77:33. We expect patient traffic to continue its steady growth as the COEs attract referrals and marketing efforts boost awareness.
+ Bed occupancy rose to 61% from 59% a year ago despite the total number of operational beds remaining the same at 437. HMI continues to increase its bed capacity with the new extension block at Regency, which begun construction last quarter. Regency’s bed count will increase by 380 beds upon completion in 2021, with the potential to expand to 500 beds by utilising shell spaces set aside.
The Negative
– Starmed’s gestation costs to weigh down PATMI in the next 2 to 3 years. Core PATMI of RM13.0mn fell 15.4% YoY. Excluding the Starmed’s gestation costs, 3Q19’s core PATMI would have increased by 10.0% YoY, indicating a RM4.0mn net loss from Starmed in 3Q19 (2Q19: RM2.9mn). Top line contribution from Starmed is immaterial at this point. Starmed’s net loss this quarter includes the depreciation (inclusive of new property purchases in Jan 2019) and finance costs of six levels of Starmed. Hence, we expect this quarter’s net profit impact from Starmed to be more indicative of moving forward. We raise our EBIT loss assumptions on Starmed to RM 6-9mn for the first three years of operation, resulting in lower EBITDA for FY19e and FY20e by 3.3% and 5.8% respectively.
Outlook
We remain positive on the outlook for HMI due to its resilient hospital operations and growth trajectory to meet the growing demand.
Mahkota (Malaysia, Melaka)
Mahkota’s Cancer Centre will be launching Tomotherapy services and it will be the only hospital in South of Kuala Lumpur that offers this cancer treatment. Progressive upgrading and refurbishing of older wards will continue to maintain a new and consistently upgraded facility for the patients. Undertaking preliminary assessments to expand Mahkota.
Regency (Malaysia, Johor)
Construction of the new extension block begun last quarter. Upon its targeted commissioning in 2021, Regency will become a 380-bed tertiary hospital, with the potential to expand capacity to 500 beds.
Regency’s new competitors. (i) KPJ Bandar Dato Onn (Johor): started operations and located 10 minutes away from Regency. (ii) Columbia Asia South Key (Johor): expected to open within next few months. Mainly a secondary care hospital and does not have the full set-up that Regency does. Regency will face increasing competition for specialists, staff and patients but there is currently no impact from both competitors as both hospitals are still in the early stages of operation. HMI’s strategy is to expand faster, develop their Centre of Excellences and recruit more specialists.
StarMed Specialist Centre (Singapore)
Starmed currently has 30 accredited specialists. Average bill size is below the private healthcare average and the affordability is due to lower overheads costs associated with a smaller set-up and lower staff costs. In comparison to a hospital, Starmed does not need to maintain an emergency wing nor operate for 24 hours because its patients usually undergo minimally invasive procedures that do not require overnight stays.
Primary Care – Plus Medical Holdings Pte Ltd (Singapore)
Plus targets to have more than 40 primary care clinics in Singapore in 3 years. HMI invested an initial S$4.2mn for a 28% stake in a chain of 16 primary care clinics in Singapore on 15 Mar 2019. HMI’s stake may increase over time, subject to further requests for funding and satisfaction of certain conditions.
Investment Action
Maintain BUY with a lower DCF-derived TP of S$0.73 (previously S$0.77). Our lower target price was due to the incorporation gestation costs of RM6-9mn EBIT loss for the first three years of Starmed’s operation. Despite the suppression of earnings in the near term due to gestation costs, we maintain our view that HMI will benefit from the socioeconomic tailwinds arising from Malaysia’s (i) public and private initiatives to improve infrastructure and regional connectivity; (ii) increasing domestic insurance take-up rate; (iii) favourable demographics; and (iv) cost competitive pricing compared to regional peers. Potential risks include (i) greater competition; (ii) disadvantageous regulatory changes; and (iii) longer than expected gestation period.
Important Information
This report is prepared and/or distributed by Phillip Securities Research Pte Ltd ("Phillip Securities Research"), which is a holder of a financial adviser’s licence under the Financial Advisers Act, Chapter 110 in Singapore.
By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.
The information and any analysis, forecasts, projections, expectations and opinions (collectively, the “Research”) contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.
Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.
This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient’s own independent verification and exercise of judgment. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.
Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.
Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.
Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.
To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.
The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.
This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.
This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.
IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSE
Where the report contains research analyses or reports from a foreign research house, please note:
Min Ying covers the Banking and Finance sectors. She has experience in external audit and corporate tax roles.
She graduated with a Bachelor of Accountancy with a major in Finance from SMU.
